BURLINGTON, Mass., June 26, 2026
PharmaEssentia USA Corporation announced that the U.S. Food and Drug Administration (FDA) has approved and the company will launch the BESREMi Pen™ (ropeginterferon alfa-2b-njft) for the treatment of adult patients with Polycythemia Vera (PV). The newly approved pre-filled pen device provides a more convenient self-administration option compared with the currently available pre-filled syringe, helping simplify long-term treatment for patients living with the rare blood cancer. The company expects the BESREMi Pen to become commercially available across the United States in the coming weeks, representing another important milestone in PharmaEssentia’s hematology portfolio.
FDA Approval Brings Easier Self-Administration for PV Patients
The approval introduces a patient-friendly delivery device designed to improve treatment convenience while supporting better adherence to therapy. BESREMi is the first and only long-acting interferon approved for Polycythemia Vera, and the addition of the pre-filled pen allows eligible patients to administer treatment more easily at home. PharmaEssentia stated that the device reflects its continued commitment to improving both therapeutic outcomes and the overall patient experience. Company leadership emphasized that combining innovative biologic medicines with user-friendly delivery technologies can help patients manage chronic blood disorders with greater confidence and consistency throughout long-term treatment.
Clinical Experts Highlight Benefits of the BESREMi Pen
According to Dr. John Mascarenhas, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai, treatment consistency remains essential for successfully managing Polycythemia Vera. He noted that the FDA approval of the BESREMi Pen provides physicians and patients with an important new administration option that may improve treatment adherence by simplifying the injection process. PharmaEssentia also highlighted that the new device was developed in response to patient needs, offering greater convenience while maintaining the proven efficacy and safety profile of ropeginterferferon alfa-2b-njft already established in clinical practice..
Advertisement
PharmaEssentia Strengthens Global Hematology Leadership
The FDA approval further strengthens PharmaEssentia Corporation’s position as a global biopharmaceutical innovator focused on hematology, oncology, and immunology. Headquartered in Taipei, Taiwan, with expanding operations across the United States, Japan, China, and Korea, the company continues investing in innovative biologics and advanced drug delivery technologies. The launch of the BESREMi Pen represents another strategic step toward improving the quality of life for patients with rare hematologic diseases while reinforcing PharmaEssentia’s long-term commitment to delivering innovative treatment solutions worldwide.
Source: PharmaEssentia, press release
